A Dose-response of the Effects of Exendin-9,39 on GI Symptoms and Food Intake
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Obesity Weight Loss |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 20 - 70 |
| Updated: | 3/9/2019 |
| Start Date: | May 2014 |
| End Date: | July 2019 |
A Dose-response Study of the Effects of Exendin-9,39 on Gastrointestinal Symptoms and Food Intake.
Exendin-(9,39) has been shown to have effects on beta-cell function, and after gastric
bypass, to accelerate gastrointestinal transit. - infused at rates of 300pmol/kg/min. Given
that gastrointestinal transit is typically delayed by Glucagon-Like Peptide-1 (GLP-1) and
also that this hormone causes decreased food intake through increased satiation, it is
reasonable to expect an effect of Exendin-9,39 on appetite. This may help explain the effects
of gastric bypass on food intake. To examine the effect of Exendin on food intake we propose
a dose-response study to determine whether the compound has effects in a dose-dependent
fashion. We will examine the presence of gastrointestinal symptoms as well as food intake in
the immediate aftermath of a test meal and the subsequent hours.
bypass, to accelerate gastrointestinal transit. - infused at rates of 300pmol/kg/min. Given
that gastrointestinal transit is typically delayed by Glucagon-Like Peptide-1 (GLP-1) and
also that this hormone causes decreased food intake through increased satiation, it is
reasonable to expect an effect of Exendin-9,39 on appetite. This may help explain the effects
of gastric bypass on food intake. To examine the effect of Exendin on food intake we propose
a dose-response study to determine whether the compound has effects in a dose-dependent
fashion. We will examine the presence of gastrointestinal symptoms as well as food intake in
the immediate aftermath of a test meal and the subsequent hours.
Inclusion Criteria:
- Subjects who have undergone Roux en-Y Gastric Bypass at least 6 months prior to
enrollment in the study.
- Subjects without active systemic illness.
Exclusion Criteria:
- Subjects <20 years of age will not be studied to minimize the possibility of type 1
diabetes.
- Subjects >70 years of age will not be studied to minimize the potential confounding
effects of age on glucose tolerance.
We found this trial at
1
site
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
